Human disease
myotonic dystrophy type 1
Mondo defines it as: “Steinert disease, also known as myotonic dystrophy type 1, is a muscle disease characterized by myotonia and by multiorgan damage that combines various degrees of muscle weakness, arrhythmia and/or cardiac conduction disorders, cataract, endocrine damage, sleep disorders and baldness.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 699 | Myotonic dystrophy | OMIA's OMIM numbers | 1 | Human disease |
29.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Delpacibart Etedesiran | None of these genes | Phase 3 |
| Metformin | None of these genes | Phase 3 |
| Mexiletine | None of these genes | Phase 3 |
| Zeleciment Basivarsen | None of these genes | Phase 3 |
| Methylphenidate | None of these genes | Phase 2/3 |
| Tideglusib | None of these genes | Phase 2/3 |
| Mecasermin | None of these genes | Phase 2 |
| Pitolisant | None of these genes | Phase 2 |
| Rinfabate | None of these genes | Phase 2 |
| Amitriptyline | None of these genes | Phase 1/2 |
| Amlodipine | None of these genes | Phase 1 |
| Ranolazine | None of these genes | Phase 1 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.